Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
Avacta Group PLC (AIM:AVCT) Avacta to Present at Leerink Healthcare Conference
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
Avacta Group PLC (AIM:AVCT) Agreement to Sell Launch Diagnostics and a Corporate Update
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has agreed to sell
Avacta Group PLC (AIM:AVCT) Avacta Announces Data from AVA6000 Phase 1 trial
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
Avacta Group PLC (AIM:AVCT) Appoints Brian Hahn as Chief Financial Officer
Brian brings 25 years’ senior financial and operational experience, including leading GlycoMimetics’ Nasdaq IPO and financial operations
Avacta Group (AIM:AVCT) Leading the Way in Precision Cancer Therapies
Avacta Group (AIM: AVCT) is redefining cancer treatment through its proprietary pre|CISION™ platform, which enables the development of peptide drug conjugates (PDCs) that deliver chemotherapy drugs directly to tumours.
Avacta’s progress with AVA6000 and the pre|CISION™ platform positions it as a standout in precision medicine.
Avacta Group (AIM: AVCT) is redefining cancer treatment through its proprietary pre|CISION™ platform, which enables the development of peptide drug conjugates (PDCs) that deliver chemotherapy drugs directly to tumours.
Avacta Group (AIM:AVCT) Leading the Way in Precision Cancer Therapies
Avacta Group (AIM: AVCT) is redefining cancer treatment through its proprietary pre|CISION™ platform, which enables the development of peptide drug conjugates (PDCs) that deliver chemotherapy drugs directly to tumours.
Avacta Group PLC (AIM:AVCT) Completion of Dose Escalation and RDE Arms
Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment
Top 12 Small-Cap Stocks to Watch in 2025: Part 1 – Avacta
As we kick off our series on the top small-cap stocks to watch in 2025, Part 1 focuses on promising companies operating within the mining, energy, and biotech sectors. These
Avacta Group PLC (AIM:AVCT) R&D Spotlight focusing on pipeline advances
R&D Spotlight focusing on pre|CISION® technology and pipeline advances
Avacta (AIM:AVCT) Review: The British Biotech Disrupting Cancer Treatment
Who is Avacta?